Biovation was focused on the development of antibody and protein based pharmaceuticals and contract research. The company was sold in 2001 to Merck KGaA and made SEP a return of 8 times money invested.
Biovation was focused on the development of antibody and protein based pharmaceuticals and contract research. The company was sold in 2001 to Merck KGaA and made SEP a return of 8 times money invested.